Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CVRS
CUSIPN/A
Phone+1-508-6533335
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-323.84%
Return on Equity-110.93%
Return on Assets-88.11%
Miscellaneous
EmployeesN/A
Outstanding Shares188,960,000
Market Cap$272.68 million
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) posted its earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to analysts' expectations of $3 million. Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%. View Corindus Vascular Robotics' Earnings History.
When is Corindus Vascular Robotics' next earnings date?
What price target have analysts set for CVRS?
3 brokers have issued twelve-month price objectives for Corindus Vascular Robotics' shares. Their predictions range from $1.00 to $2.00. On average, they expect Corindus Vascular Robotics' share price to reach $1.6667 in the next year. This suggests a possible upside of 81.2% from the stock's current price. View Analyst Price Targets for Corindus Vascular Robotics.
What is the consensus analysts' recommendation for Corindus Vascular Robotics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corindus Vascular Robotics.
Are investors shorting Corindus Vascular Robotics?
Corindus Vascular Robotics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 13,683,479 shares, an increase of 0.9% from the July 13th total of 13,557,434 shares. Based on an average daily trading volume, of 832,844 shares, the days-to-cover ratio is presently 16.4 days. Approximately 16.8% of the shares of the stock are sold short. View Corindus Vascular Robotics' Current Options Chain.
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include Consort Medical (CSRT), Ekf Diagnostics (EKF), Bioquell (BQE), Immunodiagnostic Systems (IDH), Zecotek Photonics (ZMS), Theralase Technologies (TLT), LiDCO Group (LID), Medaphor Group (MED), InspireMD (NSPR), Lucid (LCDX), Verisante Technology (VRS) and Deltex Medical Group (DEMG).
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the folowing people:
- Mr. Mark J. Toland, CEO, Pres & Director (Age 48)
- Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 48)
- Mr. Tal Wenderow, Co-Founder and Exec. VP of International & Bus. Devel.
- Mr. Doug Teany, Chief Operating Officer
- Ms. Nora Dutta, VP of HR
Has Corindus Vascular Robotics been receiving favorable news coverage?
Headlines about CVRS stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corindus Vascular Robotics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 47.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Corindus Vascular Robotics.
Who are Corindus Vascular Robotics' major shareholders?
Corindus Vascular Robotics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.10%), Nomura Holdings Inc. (0.66%), Migdal Insurance & Financial Holdings Ltd. (0.30%), Paloma Partners Management Co (0.26%), BlackRock Inc. (0.26%) and LMR Partners LLP (0.14%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.
Which major investors are selling Corindus Vascular Robotics stock?
Which major investors are buying Corindus Vascular Robotics stock?
CVRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nomura Holdings Inc., Paloma Partners Management Co, Migdal Insurance & Financial Holdings Ltd., LMR Partners LLP and Jane Street Group LLC. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP, Jeffrey Gold and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.
How do I buy shares of Corindus Vascular Robotics?
Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corindus Vascular Robotics' stock price today?
One share of CVRS stock can currently be purchased for approximately $0.92.
How big of a company is Corindus Vascular Robotics?
Corindus Vascular Robotics has a market capitalization of $272.68 million.
How can I contact Corindus Vascular Robotics?
Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.
MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
